Pivekimab is a human anti-IL-3 monoclonal antibody. Pivekimab can be used in the synthesis of ADC Pivekimab sunirine, which is developed for the treatment of hematological malignancies.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.